DavidBerdMD

PubMed

• 49 citations
  Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases
  Matias E. Valsecchi, Mizue Terai, David J. Eschelman, Carin F. Gonsalves, Inna Chervoneva, Jerry A. Shields, Carol L. Shields, Akira Yamamoto, Kevin L. Sullivan, MaryA...> ;Journal of Vascular and Interventional Radiology. 2015 Apr 1
• 5 citations
  A tale of two pities: autologous melanoma vaccines on the brink.
  David Berd> ;Human Vaccines & Immunotherapeutics. 2012 Aug 1
• 30 citations
  Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  Mizue Terai, Masumi Eto, Garbo D. Young, David Berd, Michael J. Mastrangelo, Yutaka Tamura, Kenichi Harigaya, Takami Sato> ;Cancer Immunology, Immunotherapy. 2012 Feb 1
• 13 citations
  Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  Adam C. Berger, Michael A. Fierro, John C. Kairys, David Berd, Takami Sato, Jocelyn Andrel, Terry Hyslop, Michael J. Mastrangelo> ;Journal of Surgical Oncology. 2012 Jan 1
• 17 citations
  Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  Amit Mahipal, Mizue Terai, David Berd, Inna Chervoneva, Kashyap Patel, Michael J. Mastrangelo, Takami Sato> ;Cancer Immunology, Immunotherapy. 2011 Apr 26
• 47 citations
  High-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal Melanoma
  Akira Yamamoto, Inna Chervoneva, Kevin L. Sullivan, David J. Eschelman, Carin F. Gonsalves, Michael J. Mastrangelo, David Berd, Jerry A. Shields, Carol L. Shields, Miz...> ;Radiology. 2009 Jul 1
• 18 citations
  Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential
  Mizue Terai, Yutaka Tamura, Vitali Alexeev, Eiko Ohtsuka, David Berd, Michael J. Mastrangelo, Takami Sato> ;Cancer Immunology, Immunotherapy. 2009 Jan 14
• 58 citations
  Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.
  Takami Sato, David J. Eschelman, Carin F. Gonsalves, Mizue Terai, Inna Chervoneva, Peter McCue, Jerry A. Shields, Carol L. Shields, Akira Yamamoto, David Berd, Michael...> ;Journal of Clinical Oncology. 2008 Nov 20
• Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (Mvax).
  Berd D, Bloome E, Schea H, Pinteur B, Fossiez F, Garcia E, Chalus L> ;J. Clin. Oncol.. 2008-05-20
• 16 citations
  A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment
  Magdolna Solti, David Berd, Michael J. Mastrangelo, Takami Sato> ;Melanoma Research. 2007 Aug 1
• 2 citations
  Whipsaw Cancer Treatments: The Role of Hormesis in Endocrine and Immune Therapies
  Richmond T. Prehn, David Berd> ;Seminars in Oncology. 2006 Dec 1
• 10 citations
  Calculation of Survival of Patients With Stage III Melanoma
  David Berd, Michael J. Mastrangelo, Takami Sato> ;Journal of Clinical Oncology. 2005 Dec 20
• 87 citations
  Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.
  Kashyap Patel, Kevin L. Sullivan, David Berd, Michael J. Mastrangelo, Carol L. Shields, Jerry A. Shields, Takami Sato> ;Melanoma Research. 2005 Aug 1
• Low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma: The final results of a pilot study.
  Schlossberg HR, Solti M, Berd D, Mastrangelo MJ, Sato T> ;J. Clin. Oncol.. 2005-06-01
• Immunoembolization of malignant liver tumor with granulocyte/macrophage colony stimulating factor (GM-CSF) and ethiodized oil followed by gelatin sponge pledgets: The ...
  Sato T, Sullivan KL, Eschelman DJ, Gonsalves CF, Terai M, Sakashita H, McCue PA, Berd D, Mastrangelo MJ> ;J. Clin. Oncol.. 2005-06-01
• 40 citations
  M-Vax: an autologous, hapten-modified vaccine for human cancer
  David Berd> ;Expert Review of Vaccines. 2004 Oct 1
• Phase I-II trial of a novel mixed haptenized autologous melanoma vaccine.
  Berd D, Sato T, Kuchar J, Riley T, Mastrangelo MJ> ;J. Clin. Oncol.. 2004-07-15
• 13 citations
  Acute extracellular acidification reduces intracellular pH, 42 degrees C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7.
  Ronald A. Coss, C. W. Storck, Phyllis R. Wachsberger, J Reilly, Dennis B. Leeper, David Berd, Miriam L. Wahl> ;International Journal of Hyperthermia. 2004 Feb 1
• 98 citations
  Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine
  David Berd, Takami Sato, Henry C. Maguire, John C. Kairys, Michael J. Mastrangelo> ;Journal of Clinical Oncology. 2004 Feb 1
• 9 citations
  Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy
  Takami Sato, Mizue Terai, Rie Yasuda, Ryuko Watanabe, David Berd, Michael J. Mastrangelo, Kenichiro Hasumi> ;Cancer Immunology, Immunotherapy. 2004 Jan 1
• 28 citations
  Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells.
  Ronald A. Coss, C. W. Storck, Constantine Daskalakis, David Berd, Miriam L. Wahl> ;Molecular Cancer Therapeutics. 2003 Apr 1
• 1 citations
  Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine
  David Berd> ;Vaccine. 2003 Jan 30
• 18 citations
  TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
  Jayanthi Manne, Michael J. Mastrangelo, Takami Sato, David Berd> ;Journal of Immunology. 2002 Sep 15
• 32 citations
  Is human aging still mysterious enough to be left only to scientists
  Aubrey D.N.J. de Grey, John W. Baynes, David Berd, Christopher B. Heward, Graham Pawelec, Gregory Stock> ;Bioessays. 2002 Jul 1
• 11 citations
  Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses
  David Berd, Takami Sato, Michael J. Mastrangelo> ;Cancer Immunology, Immunotherapy. 2002 Jun 6
• Join now to see all